This company develops culture dishes that enable researchers to test the combined effects of up to three drugs simultaneously. Their product helps identify synergistic or antagonistic interactions between compounds, accelerating drug discovery and development.
Funding
Funding not disclosed
Founders
Product
Problem
Testing drug combinations to identify synergistic or antagonistic interactions is challenging and often requires complex experimental setups. Current methods can be time-consuming and may not easily scale to test multiple combinations simultaneously. This creates a bottleneck in drug discovery and development, hindering the efficient identification of effective drug combinations.
Solution
Rx Dynamics offers CombiANT, a technology that simplifies compound interaction testing. CombiANT is designed to detect and quantify synergies and antagonisms among three-compound combinations simultaneously, using a format as simple as a petri dish. This allows researchers to easily identify beneficial or detrimental interactions between bioactive compounds such as antibiotics, pesticides, fungicides, and chemotherapeutics. By streamlining the interaction testing process, CombiANT enables faster and more efficient drug discovery and development.
Target Audience
The primary users are researchers and laboratories involved in drug discovery, microbiology, and related fields who need to efficiently test compound interactions.
Features
- Enables simultaneous testing of up to three-compound combinations.
- Facilitates the detection and quantification of synergistic and antagonistic interactions.
- Utilizes a user-friendly format similar to a standard petri dish.
- Compatible with various bioactive compounds, including antibiotics, pesticides, fungicides, and chemotherapeutics.